News Center

News Center

News Center

Industry Information

More Information

Discovery and Application of the Novel Liver Cancer Diagnostic Marker CPZ

Discovery and Application of the Novel Liver Cancer Diagnostic Marker CPZ

Further discussion on CLDN18.2, the first targeted drug is expected to be launched

Further discussion on CLDN18.2, the first targeted drug is expected to be launched

Indicator of tumor treatment efficacy: Topo II α

Indicator of tumor treatment efficacy: Topo II α

Responding to national policies, supporting the new infrastructure for domestic healthcare!

Responding to national policies, supporting the new infrastructure for domestic healthcare!

Latest Guidelines from the National Health Commission: Hereditary Factors, Classification, and Clinical Manifestations of Kidney Cancer

Latest Guidelines from the National Health Commission: Hereditary Factors, Classification, and Clinical Manifestations of Kidney Cancer

According to GLOBOCAN 2020 global cancer statistics, in 2020, the incidence of renal cell carcinoma ranked 14th among malignant tumors worldwide, lower than prostate cancer and bladder cancer of the urinary system, and the mortality rate ranked 15th. Recently, the "Guidelines for the Diagnosis and Treatment of Renal Cell Carcinoma (2022 Edition)" were released. This article summarizes parts of the etiology and clinical manifestations of renal cell carcinoma.

CSCO Guidelines Meeting | Chairman Xu Ruihua: The CSCO series of guidelines vigorously promote standardized diagnosis and treatment of tumors, emphasizing not only "bringing in" but also "going out".

CSCO Guidelines Meeting | Chairman Xu Ruihua: The CSCO series of guidelines vigorously promote standardized diagnosis and treatment of tumors, emphasizing not only "bringing in" but also "going out".

On April 23-24, 2022, the CSCO Guidelines Conference was held as scheduled. Regardless of changes in the external environment, the Chinese Society of Clinical Oncology (CSCO) has never stopped advancing the industry and improving the standardized diagnosis and treatment of tumors in China. This guidelines conference covered updates and insightful interpretations of guidelines for major tumor types. In addition, multiple guidelines were issued in areas such as tumor metastasis and adverse reactions to tumor treatments, providing a basis for clinical work and standardized diagnosis and treatment.